Negative regulation of pu.1 expression by inhibition of histone deacetylases

R. Nicholas Laribee, Michael Klemsz

Research output: Contribution to journalArticle

Abstract

PU.l is a hematopoietic-specific member of the ETS domain family of transcription factors whose correct expression is critical for normal hematopoiesis. Deregulated expression of PU. 1 in early proerythrocytes leads to the development of murine erythroleukemia, confirming PU. 1 role as an oncogene. The ability of certain inhibitors of histone deacetylases to promote the differentiation of murine erythroleukemia cell lines prompted an examination to ascertain whether these inhibitors affected PU.l expression in cell lines that normally express the gene. Treatment of the pro-T cell line 2052 and the macrophage line P388D1 with 50nM of Trichostatin A (TSA), a histone deacetylase inhibitor, showed a specific decrease in PU.l protein expression between 8 and 15 hours. Furthermore, this decrease in PU.l expression was mirrored at the mRNA level where a significant decrease in PU.l mRNA was noted between 2 and 6 hours after TSA treatment. TSA's effect on PU. 1 expression was reversible, as cells treated for a defined period of time ( 15 hours) reexpress normal levels of PU. 1 mRNA and protein if placed into fresh media (for 24 hours) without the compound. The effect on PU. 1 expression was specific since no reduction of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) levels at the mRNA or protein levels was seen. In an attempt to understand the mechanism through which TSA exerts its negative effect on PU. 1 expression, we hypothesized that TSA may promote the acetylation of PU. 1 itself. This modification could negatively affect its ability to function as a transcriptional activator and prevent it from regulating its own expression. To address this hypothesis, we performed in vitro acetylation assays using the cloned histone acetyltransferase domains (HAT) domains from three different proteins, CREB binding protein (CBP), P300, and P300/CBP Associciated Factor (P/CAF). Each HAT domain was expressed in bacteria as a GST fusion and purified. Using as our substrate recombinantly purified histidine-tagged PU.l and GST tagged PU.l DNA binding domain, we failed to detect any acetylation of either PU.l fusion proteins. All three of our HAT domain fusions acetylated purified histones and recombinant p53. In summary, we have shown that treatment of PU. 1 expressing cells with the histone deacetylase inhibitor TSA results in a specific reduction in PU. 1 mRNA and protein levels and that this negative effect on PU. 1 expression is most likely not due to direct acetylation of PU. I. We are currently assessing whether the chromatin structure of the PU.l locus and/ or factors which regulate PU.l expression are affected by the TSA treatment.

Original languageEnglish
JournalBlood
Volume96
Issue number11 PART II
StatePublished - 2000

Fingerprint

trichostatin A
Histone Deacetylases
Acetylation
Histone Acetyltransferases
Messenger RNA
CREB-Binding Protein
Leukemia, Erythroblastic, Acute
Proteins
Histone Deacetylase Inhibitors
Fusion reactions
Cell Line
Cells
Glyceraldehyde-3-Phosphate Dehydrogenases
T-cells
Macrophages
Hematopoiesis
Oncogenes
Histidine
Histones
Chromatin

ASJC Scopus subject areas

  • Hematology

Cite this

Negative regulation of pu.1 expression by inhibition of histone deacetylases. / Nicholas Laribee, R.; Klemsz, Michael.

In: Blood, Vol. 96, No. 11 PART II, 2000.

Research output: Contribution to journalArticle

@article{0293ed6b1fa34561a09d60c80cf78e17,
title = "Negative regulation of pu.1 expression by inhibition of histone deacetylases",
abstract = "PU.l is a hematopoietic-specific member of the ETS domain family of transcription factors whose correct expression is critical for normal hematopoiesis. Deregulated expression of PU. 1 in early proerythrocytes leads to the development of murine erythroleukemia, confirming PU. 1 role as an oncogene. The ability of certain inhibitors of histone deacetylases to promote the differentiation of murine erythroleukemia cell lines prompted an examination to ascertain whether these inhibitors affected PU.l expression in cell lines that normally express the gene. Treatment of the pro-T cell line 2052 and the macrophage line P388D1 with 50nM of Trichostatin A (TSA), a histone deacetylase inhibitor, showed a specific decrease in PU.l protein expression between 8 and 15 hours. Furthermore, this decrease in PU.l expression was mirrored at the mRNA level where a significant decrease in PU.l mRNA was noted between 2 and 6 hours after TSA treatment. TSA's effect on PU. 1 expression was reversible, as cells treated for a defined period of time ( 15 hours) reexpress normal levels of PU. 1 mRNA and protein if placed into fresh media (for 24 hours) without the compound. The effect on PU. 1 expression was specific since no reduction of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) levels at the mRNA or protein levels was seen. In an attempt to understand the mechanism through which TSA exerts its negative effect on PU. 1 expression, we hypothesized that TSA may promote the acetylation of PU. 1 itself. This modification could negatively affect its ability to function as a transcriptional activator and prevent it from regulating its own expression. To address this hypothesis, we performed in vitro acetylation assays using the cloned histone acetyltransferase domains (HAT) domains from three different proteins, CREB binding protein (CBP), P300, and P300/CBP Associciated Factor (P/CAF). Each HAT domain was expressed in bacteria as a GST fusion and purified. Using as our substrate recombinantly purified histidine-tagged PU.l and GST tagged PU.l DNA binding domain, we failed to detect any acetylation of either PU.l fusion proteins. All three of our HAT domain fusions acetylated purified histones and recombinant p53. In summary, we have shown that treatment of PU. 1 expressing cells with the histone deacetylase inhibitor TSA results in a specific reduction in PU. 1 mRNA and protein levels and that this negative effect on PU. 1 expression is most likely not due to direct acetylation of PU. I. We are currently assessing whether the chromatin structure of the PU.l locus and/ or factors which regulate PU.l expression are affected by the TSA treatment.",
author = "{Nicholas Laribee}, R. and Michael Klemsz",
year = "2000",
language = "English",
volume = "96",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11 PART II",

}

TY - JOUR

T1 - Negative regulation of pu.1 expression by inhibition of histone deacetylases

AU - Nicholas Laribee, R.

AU - Klemsz, Michael

PY - 2000

Y1 - 2000

N2 - PU.l is a hematopoietic-specific member of the ETS domain family of transcription factors whose correct expression is critical for normal hematopoiesis. Deregulated expression of PU. 1 in early proerythrocytes leads to the development of murine erythroleukemia, confirming PU. 1 role as an oncogene. The ability of certain inhibitors of histone deacetylases to promote the differentiation of murine erythroleukemia cell lines prompted an examination to ascertain whether these inhibitors affected PU.l expression in cell lines that normally express the gene. Treatment of the pro-T cell line 2052 and the macrophage line P388D1 with 50nM of Trichostatin A (TSA), a histone deacetylase inhibitor, showed a specific decrease in PU.l protein expression between 8 and 15 hours. Furthermore, this decrease in PU.l expression was mirrored at the mRNA level where a significant decrease in PU.l mRNA was noted between 2 and 6 hours after TSA treatment. TSA's effect on PU. 1 expression was reversible, as cells treated for a defined period of time ( 15 hours) reexpress normal levels of PU. 1 mRNA and protein if placed into fresh media (for 24 hours) without the compound. The effect on PU. 1 expression was specific since no reduction of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) levels at the mRNA or protein levels was seen. In an attempt to understand the mechanism through which TSA exerts its negative effect on PU. 1 expression, we hypothesized that TSA may promote the acetylation of PU. 1 itself. This modification could negatively affect its ability to function as a transcriptional activator and prevent it from regulating its own expression. To address this hypothesis, we performed in vitro acetylation assays using the cloned histone acetyltransferase domains (HAT) domains from three different proteins, CREB binding protein (CBP), P300, and P300/CBP Associciated Factor (P/CAF). Each HAT domain was expressed in bacteria as a GST fusion and purified. Using as our substrate recombinantly purified histidine-tagged PU.l and GST tagged PU.l DNA binding domain, we failed to detect any acetylation of either PU.l fusion proteins. All three of our HAT domain fusions acetylated purified histones and recombinant p53. In summary, we have shown that treatment of PU. 1 expressing cells with the histone deacetylase inhibitor TSA results in a specific reduction in PU. 1 mRNA and protein levels and that this negative effect on PU. 1 expression is most likely not due to direct acetylation of PU. I. We are currently assessing whether the chromatin structure of the PU.l locus and/ or factors which regulate PU.l expression are affected by the TSA treatment.

AB - PU.l is a hematopoietic-specific member of the ETS domain family of transcription factors whose correct expression is critical for normal hematopoiesis. Deregulated expression of PU. 1 in early proerythrocytes leads to the development of murine erythroleukemia, confirming PU. 1 role as an oncogene. The ability of certain inhibitors of histone deacetylases to promote the differentiation of murine erythroleukemia cell lines prompted an examination to ascertain whether these inhibitors affected PU.l expression in cell lines that normally express the gene. Treatment of the pro-T cell line 2052 and the macrophage line P388D1 with 50nM of Trichostatin A (TSA), a histone deacetylase inhibitor, showed a specific decrease in PU.l protein expression between 8 and 15 hours. Furthermore, this decrease in PU.l expression was mirrored at the mRNA level where a significant decrease in PU.l mRNA was noted between 2 and 6 hours after TSA treatment. TSA's effect on PU. 1 expression was reversible, as cells treated for a defined period of time ( 15 hours) reexpress normal levels of PU. 1 mRNA and protein if placed into fresh media (for 24 hours) without the compound. The effect on PU. 1 expression was specific since no reduction of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) levels at the mRNA or protein levels was seen. In an attempt to understand the mechanism through which TSA exerts its negative effect on PU. 1 expression, we hypothesized that TSA may promote the acetylation of PU. 1 itself. This modification could negatively affect its ability to function as a transcriptional activator and prevent it from regulating its own expression. To address this hypothesis, we performed in vitro acetylation assays using the cloned histone acetyltransferase domains (HAT) domains from three different proteins, CREB binding protein (CBP), P300, and P300/CBP Associciated Factor (P/CAF). Each HAT domain was expressed in bacteria as a GST fusion and purified. Using as our substrate recombinantly purified histidine-tagged PU.l and GST tagged PU.l DNA binding domain, we failed to detect any acetylation of either PU.l fusion proteins. All three of our HAT domain fusions acetylated purified histones and recombinant p53. In summary, we have shown that treatment of PU. 1 expressing cells with the histone deacetylase inhibitor TSA results in a specific reduction in PU. 1 mRNA and protein levels and that this negative effect on PU. 1 expression is most likely not due to direct acetylation of PU. I. We are currently assessing whether the chromatin structure of the PU.l locus and/ or factors which regulate PU.l expression are affected by the TSA treatment.

UR - http://www.scopus.com/inward/record.url?scp=33748532497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748532497&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748532497

VL - 96

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11 PART II

ER -